Drug Trial Radar · NCT06746402
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Feb 10, 2025
Primary completion
Sep 11, 2025
Study completion Sep 11, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.
Conditions
- Healthy Volunteers
Interventions
BMS-986278Drug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
MoxifloxacinDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with non-serious Adverse Events (AEs)Time frame: Until 28 days post last treatment dose
- Number of participants with Serious AEs (SAEs)Time frame: Until 28 days post last treatment dose
- Number of participants with AEs leading to study intervention discontinuationTime frame: Until 28 days post last treatment dose
- Number of participants with vital sign abnormalitiesTime frame: Up to Day 18
- Number of participants with clinical laboratory assessment abnormalitiesTime frame: Up to Day 18
- Number of participants with 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Up to Day 18
- Number of participants with physical examination abnormalitiesTime frame: Up to Day 18
- Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
- Placebo-corrected change from baseline QTcF (ΔΔQTcF)Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
ICON San Antonio
San Antonio, Texas
Local Institution - 0001
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.